Navigation Links
Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

The meta-analysis included five completed, randomized, controlled clinical trials of 16 to 52 weeks' duration, and was based on the U.S. Food and Drug Administration's (FDA's) recent guidance for evaluating CV risk in new type 2 diabetes agents. The primary endpoint for this analysis was occurrence of primary major adverse CV events (MACE). The 95 percent confidence interval for the estimated risk ratio for the primary endpoint was 0.55 to 1.34.  With the upper limit below the FDA-specified threshold of 1.8, this suggests that there is no increase in CV risk associated with SYMLIN use.  

"People with diabetes are two to four times more likely to develop cardiovascular disease because of increased risk factors such as high blood pressure, lipid disorders and obesity," said Orville G. Kolterman, M.D., senior vice president, chief medical officer at Amylin. "SYMLIN is an important tool for many patients who struggle to achieve their glucose control targets, despite their best efforts with insulin. These safety analyses confirm our findings from individual clinical studies and provide additional insight into the CV safety prof
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
2. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
3. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
4. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
5. Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting
6. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
7. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
8. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
9. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
10. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
11. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... -- Rhythm, a biopharmaceutical company developing peptide therapeutics that ... metabolic disorders, announced today that it has filed a ... and Exchange Commission (SEC) relating to the proposed initial ... number of shares to be offered and the price ... Citigroup and Cowen and Company will act ...
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Trifluoroacetic Acid ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... CRY ), a,biomaterials, medical device and tissue processing ... the FBR Capital Markets Annual,Spring Investor Conference, Thursday, May ... City., Steven G. Anderson, president and chief executive ... Time., CryoLife,s live presentation may be accessed through ...
... May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG,Pharmaceuticals, Inc. (Nasdaq: ... SSRX ), a,leading Chinese biotechnology company, ... commercialization agreement for ferumoxytol, an intravenous,iron replacement ... deficiency,anemia in chronic kidney disease (CKD) patients., ...
... May 27 CellCyte Genetics,Corporation (CellCyte) (OTC ... provide shareholders, potential investors and journalists,with accurate ... Room powered Web site: http://www.cellcyte.com ... or sources for stories from,CellCyte can access ...
Cached Biology Technology:CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference 2AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China 2AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China 3
(Date:8/27/2014)... willing to pay a premium for fruits, vegetables and ... the label claims is another matter. Now scientists studying ... to make sure farms are labelling their produce appropriately. ... Agricultural and Food Chemistry , could help prevent organic ... Food Safety Authority and the Wuerzburg University note that ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... of Warwick research finds , Gamblers show the ... new research has shown. , Researchers, led by Dr ... Psychology, conducted tests that found that both human gamblers ... high-value than low-value rewards. , Published in Biology ... show the important role that memories of previous biggest ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... Unlike most of our sensory systems that detect only one ... detecting both chemical and mechanical stimuli to improve how we ... in the March issue of Nature Neuroscience. , This ... reaction in olfactory nerve cells, which control how our brain ...
... the University of Liverpool have found how two molecules fight ... , Researchers discovered that a large protein, which forms a ... secondary tumours, is attacked by a small protein that exists ... breast, lung and colorectal cancer, infected cells lose growth control ...
... onset of type 1 diabetes in mice prone to ... on the surface of immune T-cells. According to the ... January issue of the journal Diabetes, have significant implications ... More than 700,000 Americans have type 1 diabetes, an ...
Cached Biology News:Penn study on olfactory nerve cells shows why we smell better when we sniff 2Scientists discover how body fights to control spread of cancer 2Antibody therapy prevents type 1 diabetes in mice 2
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... synthetic peptide whose sequences are derived from mouse resistin protein. ... - S - M - P - L - C - ... - D - K - K - I - K - ... used for neutralization and control experiments with the polyclonal antibody that ...
... Imaging System, Basic Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
Biology Products: